NCT07708805Recruiting
Quantitative Myocardial Perfusion Imaging Assessment by SPECT/CT
Quantitative Myocardial Perfusion Imaging Assessment by SPECT/CT: Evaluation of Standardized Uptake Value (SUV) and Correlation With Myocardial Flow Reserve (MFR) Assessed by PET/CT
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
Myocardial perfusion single-photon emission computed tomography (SPECT) is a well-established functional imaging technique for the assessment of coronary artery disease. Recent developments in cadmium-zinc-telluride (CZT) camera technology have enabled significant reductions in acquisition time while improving image quality. Positron emission tomography (PET) myocardial imaging remains the reference standard for the quantitative assessment of myocardial blood flow (MBF) and myocardial flow reserve (MFR); however, its use is limited by high costs and restricted availability. This exploratory study aims to evaluate the feasibility of using CZT-SPECT/CT imaging as an alternative approach by assessing the absolute quantification of myocardial tracer uptake, expressed as standardized uptake values (SUV), both at rest and during stress. The primary objective is to compare the ratio of stress-to-rest SUV obtained from SPECT with MFR values measured using PET imaging. Patients under cardiology care at the University Hospital of Orléans who are scheduled for diagnostic coronary angiography or coronary CT angiography will be invited to participate. The study procedures will be integrated into their routine clinical workflow. On Day 0, participants will undergo a PET myocardial perfusion study using Rubidium-82, including measurement of MBF and MFR, with concomitant administration of 99mTc-tetrofosmin under pharmacological stress using the same vasodilator agent. A stress CZT-SPECT/CT acquisition will then be performed immediately after the PET scan. Within seven days of the initial evaluation, participants will undergo a rest CZT-SPECT/CT acquisition. Quantitative analysis of myocardial tracer uptake will subsequently be performed to derive SUV values. The overall goal of this feasibility study is to generate preliminary data to support the design of a larger-scale clinical study. Ultimately, the study seeks to determine whether standard CZT-SPECT/CT imaging could provide a simpler, faster, and more widely accessible alternative to PET myocardial perfusion imaging for functional myocardial assessment.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 13 Jul 2026
- Start date
- 21 Sept 2026
- Primary completion date
- 25 Sept 2027
- Lead sponsor
- Centre Hospitalier Régional d'Orléans
- Diseases
- Coronary artery disease
- NCT number
- NCT07708805
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 21 Sept 2026 to the primary completion date, 25 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe coronary artery disease requiring prompt revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), including left main coronary artery stenosis \>50% or other severe coronary lesions with FFR \<0.80.
- History of coronary revascularization (PCI, coronary stenting, or CABG).
- Contraindication to pharmacological stress testing for cardiac PET/SPECT, including severe hypotension, second- or third-degree atrioventricular block, or recent myocardial infarction.
Lab values
- Left ventricular ejection fraction (LVEF) \<35%.
Other
- Protected adult under legal guardianship or curatorship.
- Individual under judicial protection measures.
- Individual deprived of liberty.
- Individual not affiliated with a health insurance
- Pregnant or breastfeeding woman.
Who the study is looking for
- Participant has provided informed consent to participate in the study.
- Age ≥ 18 years.
- Patients referred for functional cardiac imaging assessment (SPECT or PET) following diagnostic coronary CT angiography (CCTA) or invasive coronary angiography demonstrating either:
- moderate coronary atherosclerosis without significant coronary stenosis (\<50% stenosis), or
- coronary lesions for which functional cardiac imaging assessment or medical therapy is indicated.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Universitaire d'Orléans Coordinator of this site? Confirm its status | ORLEANS | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.